X-Linked Adrenoleukodystrophy: Clinical Trials

3 trials for X-Linked Adrenoleukodystrophy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 withdrawn, 1 completed. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Withdrawn 2, Completed 1
Phase 21Withdrawn 1

Follow X-Linked Adrenoleukodystrophy: new trials by email Literature Review of X-Linked Adrenoleukodystrophy trials Research Report on X-Linked Adrenoleukodystrophy

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy
Sobetirome (NV1205) - X-Linked Adrenoleukodystrophy
Phase 1 / Phase 2WithdrawnNeuroVia, Inc.2018-08-012019-03-07
A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy
vitamin D3 - X-linked Adrenoleukodystrophy
Phase 1CompletedStanford University212016-11-212022-06-09
Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)
Sobetirome - X-Linked Adrenoleukodystrophy, Adrenomyeloneuropathy
Phase 1WithdrawnThomas S. Scanlan2013-04-012014-02-14

Narrower conditions

Adrenoleukodystrophy (3)  ·  Demyelinating Diseases (1)  ·  Inflammation (1)  ·  Thyroid Diseases (1)

Broader conditions

Adrenal Gland Diseases (3)  ·  Adrenal Insufficiency (3)  ·  Brain Diseases (3)  ·  Brain Diseases, Metabolic (3)  ·  Brain Diseases, Metabolic, Inborn (3)  ·  Central Nervous System Diseases (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Endocrine System Diseases (3)  ·  Genetic Diseases, Inborn (3)  ·  Genetic Diseases, X-Linked (3)  ·  Hereditary Central Nervous System Demyelinating Diseases (3)  ·  Heredodegenerative Disorders, Nervous System (3)  ·  Intellectual Disability (3)  ·  Leukoencephalopathies (3)  ·  Metabolic Diseases (3)

Interventions

GC 1 compound (2)  ·  Cholecalciferol (1)  ·  Vitamin D (1)

Sponsors

NeuroVia, Inc. (1)  ·  Stanford University (1)  ·  Thomas S. Scanlan (1)

Countries

United States (2)  ·  Argentina (1)  ·  Australia (1)  ·  Chile (1)  ·  Colombia (1)  ·  France (1)  ·  Russia (1)  ·  Ukraine (1)  ·  United Kingdom (1)

Top investigators

David Koeller, MD (1)  ·  John Henderson, MD (1)  ·  Keith Van Haren, MD (1)

NIH funding

K23NS087151 (1)